“Don has been an invaluable advisor and guide to our team. As a longtime friend and colleague in the field of cryogenic electron microscopy, both in his role as CEO at FEI and later, at ThermoFisher, I have long valued his expertise, scientific curiosity, and sense of humor,” said Sriram Subramaniam, Gandeeva Founder and CEO. “Don’s wisdom is encoded into the DNA of Gandeeva Therapeutics. We will miss our friend.”

Don Kania earned his MS in physics and PhD in engineering from the University of Michigan. He was the Chief Executive Officer of FEI Company, a world-leading manufacturer of electron microscopes, from 2006 until the company was sold to Thermo Fisher in 2016. During his tenure, revenue doubled, while profitability and share price increased by five-fold.

About Gandeeva Therapeutics  

Gandeeva Therapeutics is a precision medicine company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva’s structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT), hit identification by screening virtual and fragment libraries (HYPERFOCUS), and lead optimization (CRYO-CADD). Gandeeva has a robust preclinical oncology pipeline targeting difficult-to-treat cancers with novel protein interaction modulators such as interfacial glues (iGlues) and allosteric inhibitors. Gandeeva is headquartered in the Greater Vancouver area, Canada. For more information, please visit www.gandeeva.com or follow us on LinkedIn and Twitter. 

Media Contact 

Emily Wight 
Communications Manager, Gandeeva Therapeutics 
[email protected] 
+1 778-726-4194 

The post Gandeeva Therapeutics mourns the passing of Don Kania, Board Chair appeared first on Gandeeva Therapeutics.